J&J Cypher Panel Date Presages Year-End Approval; Achieve Cleared In EU
This article was originally published in The Gray Sheet
Executive Summary
Clinical data to be reviewed by FDA's Circulatory System Devices Panel Oct. 22 will include nine-month SIRIUS trial safety results on Johnson & Johnson's sirolimus-eluting Cypher stent
You may also be interested in...
Drug-Eluting Stent Payment Based On UK Prices Sets Precedent – MedPAC
The Medicare Payment Advisory Commission expressed concern over the potential precedent set by the Centers for Medicare & Medicaid Services' recent decision to base the payment rate for drug-eluting stents on overseas prices
Drug-Eluting Stent Payment Based On UK Prices Sets Precedent – MedPAC
The Medicare Payment Advisory Commission expressed concern over the potential precedent set by the Centers for Medicare & Medicaid Services' recent decision to base the payment rate for drug-eluting stents on overseas prices
German DRG For Drug-Eluting Stents On Horizon, J&J/Cordis Hopes
Johnson & Johnson/Cordis is in negotiations with the German Institute for Medical Documentation and Information (DIMDI) to obtain an OPS procedural code for its Cypher drug-eluting stent